Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RAB9A | P51151 | 11/20 | 0.34 |
| ▸ | HPGD | P15428 | 3/20 | 0.34 |
| ▸ | NPC1 | O15118 | 8/20 | 0.33 |
| ▸ | SMN1; SMN2 | Q16637 | 6/20 | 0.33 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.33 |
| ▸ | ALDH1A1 | P00352 | 8/20 | 0.33 |
| ▸ | TP53 | P04637 | 1/20 | 0.32 |
| ▸ | MAPT | P10636 | 2/20 | 0.31 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.31 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.31 |
| ▸ | LMNA | P02545 | 1/20 | 0.30 |
| ▸ | HTT | P42858 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL345290 | 0.89 | SMYD3 (0.33) | RAB9AHPGDNPC1SMN1; SMN2ALDH1A1 | |
| Hydrochloric Acid SCHEMBL344560 | 0.84 | SMYD3 (0.35) | RAB9AHPGDNPC1SMN1; SMN2ALDH1A1 | |
| SCHEMBL345771 | 0.77 | MAPT (0.35) | NPC1SMN1; SMN2ALDH1A1MAPTLMNA | |
| SCHEMBL345648 | 0.76 | HRH4 (0.38) | RAB9AHPGDNPC1SMN1; SMN2HSD17B10 | |
| Hydrochloric Acid SCHEMBL346103 | 0.76 | SMYD3 (0.32) | RAB9ANPC1SMN1; SMN2ALDH1A1 | |
| Hydrochloric Acid SCHEMBL9994167 | 0.71 | SMYD3 (0.33) | RAB9ANPC1SMN1; SMN2ALDH1A1 | |
| Hydrochloric Acid SCHEMBL345732 | 0.70 | SMYD3 (0.38) | RAB9ANPC1SMN1; SMN2ALDH1A1 | |
| Trifluoroacetic Acid SCHEMBL9994525 | 0.69 | SMYD3 (0.35) | — | |
| SCHEMBL345257 | 0.67 | PKM (0.35) | ALDH1A1KDM4E | |
| SCHEMBL345259 | 0.67 | HRH4 (0.40) | RAB9ANPC1MAPK1TP53MAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120015950-A1 | CARBAMATE DERIVATIVES OF ALKYL-HETEROCYCLES, PREPARATION THEREOF AND THERAPEUTIC USE THEREOF | SANOFI-AVENTIS (FR) | 2012-01-19 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120015950-A1 | CARBAMATE DERIVATIVES OF ALKYL-HETEROCYCLES, PREPARATION THEREOF AND THERAPEUTIC USE THEREOF | INTS9, CDK8, SCN8A | RAB9A 331/4885HPGD 2068/4885NPC1 1821/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.